fengabine

Fengabine is a small molecule antidepressant that was investigated primarily for the treatment of major depressive disorder. It is a benzylidene derivative and has been described as a GABAmimetic or GABAergic agent due to its antidepressant effects being reversed by GABAA receptor antagonists such as bicuculline. However, fengabine does not directly bind to GABA receptors nor inhibit GABA transaminase (GABA-T). Its precise mechanism of action remains unknown. In clinical trials, fengabine demonstrated efficacy comparable to tricyclic antidepressants but with a more rapid onset and significantly fewer side effects, notably lacking sedative properties. Despite reaching phase III clinical trials in France under Synthélabo (now part of Sanofi), development was discontinued and it was never marketed[1][3][4][5][7][10].

Other names

fengabineSL 79229SL79229SL-79229